A 74-year-old female with generalized anxiety disorder was started on escitalopram 5 mg daily eight weeks ago. At follow-up, her GAD-7 score has decreased from 18 to 11, representing a 39% reduction. She reports less constant worry and improved sleep onset latency, but continues to endorse persistent somatic anxiety symptoms including muscle tension, restless feelings, and fatigue. She denies falls, cognitive changes, or medication side effects. Her daughter reports the patient appears somewhat less anxious overall but remains notably tense and has difficulty relaxing during family gatherings. The PMHNP is evaluating the treatment response in the context of geriatric prescribing considerations. Which of the following best represents the appropriate evaluation of this patient's treatment trajectory?